Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Theriva Biologics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 18 | 21 | +3 |
| Shares | 1.01M | 1.06M | +55.3K (+5.5%) |
| Value | $1.01M | $572.8K | −$434.9K (−43.2%) |
New holders (4)
Institutions that held Theriva Biologics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 17,334 | $9.35K | 0.00% |
| Two Sigma Securities, LLC | 15,968 | $8.61K | 0.00% |
| FMR LLC | 100 | $54 | 0.00% |
| JPMorgan Chase & Co | 15 | $8 | 0.00% |
Sold out (1)
Institutions that held Theriva Biologics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| UBS Group AG | 5,933 | $5.93K |